Two years post affordable medicines facility for malaria program: availability and prices of anti-malarial drugs in central Ghana
| العنوان: | Two years post affordable medicines facility for malaria program: availability and prices of anti-malarial drugs in central Ghana |
|---|---|
| المؤلفون: | Anthony Kwarteng, Seth Owusu-Agyei, Kwaku Poku Asante, Alexander Freeman, Seeba Amenga-Etego, Lawrence Gyabaa Febir |
| المصدر: | Journal of Pharmaceutical Policy and Practice, Vol 10, Iss 1, Pp 1-7 (2017) Journal of Pharmaceutical Policy and Practice |
| بيانات النشر: | BMC, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Anti malarial, Artemether/lumefantrine, 030231 tropical medicine, lcsh:RS1-441, Pharmacy, Ghana, Green leaf, lcsh:Pharmacy and materia medica, 03 medical and health sciences, 0302 clinical medicine, medicine, 030212 general & internal medicine, Market share, Subsidy, Socioeconomics, Global fund, business.industry, Research, Health Policy, Kintampo, Significant difference, lcsh:RM1-950, medicine.disease, AMFm, Artemisinin-based combination therapy, Malaria, lcsh:Therapeutics. Pharmacology, Rural area, business, medicine.drug |
| الوصف: | Background The Affordable Medicines Facility for malaria (AMFm) Program was a subsidy aimed at artemisinin-based combination therapies (ACTs) in order to increase availability, affordability, and market share of ACTs in 8 malaria endemic countries in Africa. The WHO supervised the manufacture of the subsidized products, named them Quality Assured ACTs (QAACT) and printed a Green Leaf Logo on all QAACT packages. Ghana began to receive the subsidized QAACTs in 2010. Methods A cross-sectional stock survey was conducted at 63 licensed chemical shops (LCS) and private pharmacies in two districts of the Brong-Ahafo region of Ghana to determine the availability and price of all anti-malarial treatments. Drug outlets were visited over a 3-weeks period in October and November of 2014, about 2 years after the end of AMFm program. Results At least one QAACT was available in 88.9% (95% CI 80.9% – 96.8%) of all drug outlets with no difference between urban and rural locations. Non-Assured ACTs (NAACT) were significantly more available in urban drug outlets [75.0% availability (95% CI 59.1% – 90.9%)] than in rural drug outlets [16.1% availability (95% CI 2.4% – 29.9%)]. The top selling product was Artemether Lumefantrine with the Green Leaf Logo, a QAACT. There was a significant difference in the mean price of a QAACT [$1.04 USD (95% CI $0.98 – $1.11)], and the mean price of a NAACT in both the urban and rural areas [$2.46 USD (95% CI $2.11 – $2.81)]. There was no significant difference in the price of any product that was available in urban and rural settings Conclusion About 2 years after the AMFm program, subsidized QAACTs in Ghana were widely available and more affordable than NAACTs in the Kintampo North District and Kintampo South Municipality of Ghana. The AMFm program appeared to have mostly succeeded in making QAACTs available and affordable. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2052-3211 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3de760eae1022441f947f9cb0cb9e8d0 http://link.springer.com/article/10.1186/s40545-017-0103-0 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....3de760eae1022441f947f9cb0cb9e8d0 |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. 
PDF full text from Publisher | تدمد: | 20523211 |
|---|